Papers - HATAKEYAMA SHINGO
-
術前化学療法抵抗性のSarcomatiod variantを伴う筋層浸潤性膀胱癌に対しペンブロリズマブで病理学的完全奏功した一例
尾崎 佑輔, 岡本 哲平, 小西 栄, 小玉 寛健, 堀口 裕貴, 岩村 大径, 小島 由太, 成田 拓磨, 飛澤 悠葵, 米山 徹, 盛 和行, 山本 勇人, 畠山 真吾, 米山 高弘, 橋本 安弘, 大山 力
泌尿器外科 35 ( 4 ) 360 - 360 2022.4
-
左腎に晩期再発をきたした卵巣顆粒膜細胞腫の一例
富樫 赳, 橋本 安弘, 堀口 裕貴, 小玉 寛健, 成田 拓磨, 小島 由太, 岩村 大径, 岡本 哲平, 米山 徹, 山本 勇人, 畠山 真吾, 米山 高弘, 大山 力
泌尿器外科 35 ( 4 ) 355 - 356 2022.4
-
免疫チェックポイント阻害剤に対してMixed responseを呈し小腸転移を生じた進行性腎癌の一例
小玉 寛健, 畠山 真吾, 富樫 赳, 堀口 裕貴, 成田 拓磨, 岩村 大径, 小島 由太, 岡本 哲平, 米山 徹, 山本 勇人, 米山 高弘, 橋本 安弘, 大山 力, 鬼島 宏, 後藤 慎太郎
泌尿器外科 35 ( 4 ) 356 - 356 2022.4
-
乳腺葉状腫瘍と酷似する組織を伴った膀胱癌の1例
濱野 逸人, 畠山 真吾, 米山 美穂子, 濱谷 智子, 百田 匡毅, 成田 拓磨, 小島 由太, 岩村 大径, 岡本 哲平, 米山 徹, 山本 勇人, 米山 高弘, 橋本 安弘, 黒瀬 顕, 大山 力
泌尿器外科 35 ( 4 ) 353 - 354 2022.4
-
Impact of body size on skin-related adverse events in advanced prostate cancer treated with apalutamide: A multicenter retrospective study.
Sasaki D, Hatakeyama S, Tanaka T, Okamoto T, Yoneyama T, Ohyama C.
2022.3
-
Management of bladder cancer in older patients.
Hatakeyama S, Narita S, Okita K, Narita T, Iwamura H, Fujita N, Inokuchi J, Matsui Y, Kitamura H, Ohyama C
Japanese journal of clinical oncology 52 ( 3 ) 203 - 213 2022.3
-
Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era - a multi-institutional retrospective study.
Kato R, Naito S, Numakura K, Hatakeyama S, Koguchi T, Kojima T, Kawasaki Y, Kandori S, Kawamura S, Arai Y, Ito A, Nishiyama H, Kojima Y, Ohyama C, Habuchi T, Tsuchiya N, Obara W
International journal of clinical oncology 27 ( 3 ) 563 - 573 2022.3
-
Simultaneous analysis of serum α2,3-linked sialylation and core-type fucosylation of prostate-specific antigen for the detection of high-grade prostate cancer.
Hatano K, Yoneyama T, Hatakeyama S, Tomiyama E, Tsuchiya M, Nishimoto M, Yoshimura K, Miyoshi E, Uemura H, Ohyama C, Nonomura N, Fujita K
British journal of cancer 126 ( 5 ) 764 - 770 2022.3
-
Effect of advanced glycation end products on nocturia or sleep disorders: A longitudinal study.
Konishi S, Hatakeyama S, Imai A, Okita K, Kido K, Ozaki Y, Uemura N, Iwane T, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C
BJUI compass 3 ( 2 ) 162 - 168 2022.3
-
Impact of prior intravesical bacillus Calmette-Guerin therapy on the effectiveness of pembrolizumab for patients with metastatic urothelial carcinoma.
Taoka R, Kobayashi T, Hidaka Y, Abe H, Ito K, Kojima T, Kato M, Kanda S, Hatakeyama S, Matsui Y, Matsushita Y, Naito S, Shiga M, Miyake M, Muro Y, Nakanishi S, Kato Y, Shibuya T, Hayashi T, Yasumoto H, Yoshida T, Uemura M, Kamiyama M, Morita S, Ogawa O, Nishiyama H, Kitamura H, Sugimoto M, Japan Urological Oncology Group
Urologic oncology 40 ( 3 ) 107.e1 - 107.e9 2022.3
-
The impact of eligibility for maintenance immunotherapy on prognosis in patients with unresectable or metastatic urothelial carcinoma.
Ozaki K, Hatakeyama S, Tanaka T, Noro D, Tokui N, Horiguchi H, Okuyama Y, Fujita N, Okamoto T, Okamoto A, Suzuki Y, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C
BJUI compass 3 ( 2 ) 139 - 145 2022.3
-
Prognostic impact of proton pump inhibitors for immunotherapy in advanced urothelial carcinoma.
Okuyama Y, Hatakeyama S, Numakura K, Narita T, Tanaka T, Miura Y, Sasaki D, Noro D, Tokui N, Okamoto T, Yamamoto H, Narita S, Yoneyama T, Hashimoto Y, Habuchi T, Ohyama C
BJUI compass 3 ( 2 ) 154 - 161 2022.3
-
Prognostic impact of eligibility for adjuvant immunotherapy in locally advanced urothelial cancer.
Miura Y, Hatakeyama S, Tanaka T, Fujita N, Horiguchi H, Okuyama Y, Kojima Y, Noro D, Tokui N, Okamoto T, Yamamoto H, Ito H, Yoneyama T, Hashimoto Y, Ohyama C
BJUI compass 3 ( 2 ) 146 - 153 2022.3
-
Real-world survival outcomes of adding docetaxel or abiraterone in patients with high-volume metastatic castration-sensitive prostate cancer: historically controlled, propensity score matched comparison with androgen deprivation therapy.
Narita S, Kimura T, Hatakeyama S, Hata K, Yanagisawa T, Maita S, Chiba S, Sato H, Kashima S, Koizumi A, Yamamoto R, Takayama K, Okane K, Ishida T, Horikawa Y, Kumazawa T, Shimoda J, Suzuki T, Ohyama C, Egawa S, Nomura K, Habuchi T
World journal of urology 2022.2
-
Management of prostate cancer in older patients.
Narita S, Hatakeyama S, Sakamoto S, Kato T, Inokuchi J, Matsui Y, Kitamura H, Nishiyama H, Habuchi T
2022.2
-
Effect of upfront combination therapy on the overall survival of patients with metastatic castration-sensitive prostate cancer: A multicenter retrospective study.
Tanaka T, Hatakeyama S, Noro D, Togashi K, Yoneyama T, Ohyama C.
International journal of urology 2022.2
-
Butyrylcholinesterase level as an independent prognostic factor for overall survival in patients on maintenance hemodialysis: a single-center retrospective study.
Fukushi K, Okamoto T, Ozaki Y, Ozaki K, Sasaki D, Miura Y, Okuyama Y, Tanaka Y, Imanishi K, Hatakeyama S, Saitoh F, Ohyama C
Clinical and experimental nephrology 26 ( 2 ) 190 - 197 2022.2
-
Effects of six-cycle completion and earlier use of radium-223 therapy on prognosis for metastatic castration-resistant prostate cancer: A real-world multicenter retrospective study.
Sasaki D, Hatakeyama S, Kawaguchi H, Hatayama Y, Ishibashi Y, Kusaka A, Noro D, Tanaka T, Ito H, Okuyama Y, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Aoki M, Ohyama C
Urologic oncology 40 ( 2 ) 64.e1 - 64.e8 2022.2
-
Cohort profile: Alliance for Quality Assessment in Healthcare-Dialysis (AQuAH-D) prospective cohort study of patients on haemodialysis in Japan.
BMJ Open 2022.1
-
The influence of gut microbiome on progression of overactive bladder symptoms: a community-based 3-year longitudinal study in Aomori, Japan.
Okuyama Y, Okamoto T, Sasaki D, Ozaki K, Songee J, Hatakeyama S, Mikami T, Ohyama C
International urology and nephrology 54 ( 1 ) 9 - 16 2022.1